Bone Biologics completes merger with AFH Acquisition X
Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the
Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp and anticipates that trading in the Company’s common stock will commence on the
The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") in which Actavis is
Dr. Vaughan Clift, Ampio’s Chief Regulatory Officer explained "The seven (7) patient ‘open label’ phase of the 47 patient STRUT study was performed to assure that multiple injections
As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity
The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah
The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA
The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. Dr. Nicholas
Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The
The company also announced the establishment of its corporate headquarters in Cambridge, Massachusetts, where Patrick Anquetil, Ph.D., MBA and Mark Philip, Ph.D., MBA serve as chief executive officer
Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement